FGL1 accelerates hepatocyte proliferation and protects against liver injury by activating the EGFR/ERK cascade through the Src-dependent pathway, exhibiting its potential to be used to treat fulminant hepatic failure in humans (18–20). This evidence concerns the gene EGFR and Fulminant hepatic failure.